Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. The company is headquartered in Bay Harbor Islands, Florida and currently employs 2 full-time employees. The company went IPO on 2017-06-27. The firm is focused on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201 for the treatment of spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's Disease), intravenous tramadol (IV tramadol) for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders. AJ201 is designed to modify SBMA through multiple mechanisms, including degradation of the mutant androgen receptor (AR) protein and stimulation of the Nrf1 and Nrf2 pathways, which are involved in protecting cells from oxidative stress that can lead to cell death. Baergic’s pipeline consists of a single compound, BAER-101, a novel α2/3 subtype-selective GABA A positive allosteric modulator.
Follow-Up Questions
Who is the CEO of Avenue Therapeutics Inc?
Dr. Alexandra Maclean is the Chief Executive Officer of Avenue Therapeutics Inc, joining the firm since 2022.
What is the price performance of ATXI stock?
The current price of ATXI is $0.7301, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Avenue Therapeutics Inc?
Avenue Therapeutics Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Avenue Therapeutics Inc market cap?
Avenue Therapeutics Inc's current market cap is $2.3M
Is Avenue Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Avenue Therapeutics Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
